Bioline RX Ltd Sponsored ADR (BLRX) AI Stock Analysis

• Market Cap: $15.14M
• Dividend Yield: N/A
• Average Volume (3M): 23.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: -41.76%
• EPS Growth: 87.36%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 4,351,358
• 10 Day Avg. Volume: 24,146
• 30 Day Avg. Volume: 23,614
• PEG Ratio: 0.84
• Price to Book (P/B): 50.79
• Price to Sales (P/S): 23.63
• P/FCF Ratio: -15.56
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $12.00
• Price Target Upside: 259.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $3.50 ▲(4.79% Upside)

BioLine RX Ltd's overall stock score reflects significant revenue growth and strategic initiatives, but is weighed down by ongoing profitability challenges and a bearish technical outlook. The company's strong cash position and potential in innovative treatments are promising, yet current revenue generation and market penetration remain hurdles.

Positive Factors

Joint Venture with Hemispherian

The JV with Hemispherian expands BioLineRx's pipeline into high-need cancer indications, enhancing its market position and potential revenue streams.

Strong Cash Position

A robust cash position supports operational stability and strategic investments, ensuring the company can sustain its R&D efforts into 2027.

USPTO Patent Allowance for GLIX1

The patent allowance for GLIX1 strengthens BioLineRx's IP portfolio, securing competitive advantage and supporting long-term growth in oncology.

Negative Factors

Minimal Revenue Generation

Low revenue generation indicates slow market penetration, which could hinder the company's ability to fund future growth and R&D initiatives.

High Leverage

High leverage increases financial risk, potentially limiting the company's flexibility to invest in new opportunities or weather economic downturns.

Negative Cash Flow from Operations

Negative cash flow from operations suggests weak cash generation, which could impact long-term sustainability and the ability to fund ongoing projects.

Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model

Company Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

How the Company Makes Money

Bioline RX generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive revenue from milestone payments associated with partnerships and collaborations with larger pharmaceutical companies, as well as potential royalties from product sales once they are commercialized. Additionally, Bioline RX may engage in research agreements or licensing deals that provide upfront payments and future earnings based on the success of their drug candidates. Significant partnerships with established healthcare companies can also contribute to the company’s financial growth, especially if these collaborations lead to successful clinical trials and subsequent market approvals.

Bioline RX Ltd Sponsored ADR Financial Statement Overview

Summary

BioLine RX Ltd shows significant revenue growth, but faces challenges with negative net income and high leverage. The company's ability to raise funds is positive, yet cash flow from operations remains weak, impacting long-term sustainability.

Income Statement

The company has shown significant revenue growth from 2023 to 2024, with a surge from $4.8 million to $28.94 million. However, the net profit margin remains negative, indicating ongoing profitability challenges. The negative EBIT margin highlights persistent operating losses, though the transition from a negative to a positive EBITDA margin suggests some improvement in operational efficiency.

Balance Sheet

The debt-to-equity ratio is relatively high at 1.12, indicating a heavy reliance on debt financing which could pose risks in terms of financial stability. The equity ratio has decreased, reflecting a reduced capacity to cover assets with equity. Despite these challenges, the company maintains a positive stockholders’ equity, indicating some level of financial health.

Cash Flow

The free cash flow remains negative, although there is a notable increase in financing inflows, reflecting the company's ability to raise funds. However, the operating cash flow to net income ratio is negative, suggesting that cash generation from operations is weak, which could impact long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.25M	28.94M	4.80M	0.00	0.00	0.00
Gross Profit	10.23M	19.68M	1.11M	0.00	0.00	0.00
EBITDA	1.97M	3.92M	-57.09M	-28.50M	-24.07M	-27.59M
Net Income	-7.82M	-9.22M	-60.61M	-24.95M	-27.05M	-30.02M
Balance Sheet
Total Assets	43.27M	38.91M	63.92M	76.38M	81.39M	47.29M
Cash, Cash Equivalents and Short-Term Investments	28.16M	19.56M	42.99M	51.08M	57.13M	22.59M
Total Debt	12.60M	15.04M	11.59M	12.32M	4.65M	7.68M
Total Liabilities	23.20M	25.45M	50.70M	25.54M	13.30M	25.26M
Stockholders Equity	20.07M	13.46M	13.22M	50.84M	68.09M	22.03M
Cash Flow
Free Cash Flow	-21.20M	-43.93M	-22.91M	-26.56M	-23.67M	-23.21M
Operating Cash Flow	-21.20M	-43.87M	-22.61M	-26.24M	-23.57M	-23.21M
Investing Cash Flow	9.45M	29.37M	1.44M	4.01M	-38.22M	16.67M
Financing Cash Flow	8.72M	20.66M	15.06M	20.44M	57.75M	17.87M

Bioline RX Ltd Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Negative. The current price of 3.34 is below the 20-day moving average (MA) of 3.37, below the 50-day MA of 3.64, and below the 200-day MA of 3.73, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 41.47 is Neutral, neither overbought nor oversold. The STOCH value of 28.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLRX.

Bioline RX Ltd Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	48 Neutral	$15.14M	―	-22.03%	―	-41.76%	87.36%
SYBX	45 Neutral	$16.61M	-5.35	-27.54%	―	-100.00%	93.62%
MBRX	44 Neutral	$24.59M	-0.11	―	―	―	79.31%
PASG	44 Neutral	$24.14M	―	-87.18%	―	―	38.42%
CTXR	38 Underperform	$23.27M	―	-53.42%	―	―	18.73%
CMMB	33 Underperform	$13.81M	-1.09	-73.63%	―	―	53.19%

Bioline RX Ltd Sponsored ADR Corporate Events

BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma

On September 29, 2025, BioLineRx Ltd. announced a joint venture with Hemispherian AS to develop GLIX1, an innovative oral small molecule targeting DNA damage response in glioblastoma and other tumors. The joint venture will see Hemispherian holding 60% of the shares, with BioLineRx holding 40%, potentially increasing to 70% with further investment. The venture aims to address the significant unmet need in glioblastoma treatment, a market expected to exceed $3.8 billion annually by 2030. The FDA has cleared an IND application for a Phase 1/2a study of GLIX1, anticipated to begin in Q1 2026, highlighting the potential impact on BioLineRx’s operations and market positioning.

BioLineRx Reports Q2 2025 Financials and Strategic Updates

On August 14, 2025, BioLineRx Ltd. announced its financial results for the second quarter of 2025, highlighting a strong cash position with a runway extended into the first half of 2027. The company is actively evaluating opportunities to expand its pipeline in oncology and rare diseases, with ongoing discussions with potential partners. Clinical trials, including the CheMo4METPANC Phase 2b trial for metastatic pancreatic cancer and studies on sickle cell disease, are progressing. Financially, the company reported $0.3 million in revenues for the quarter, primarily from royalties, and a net loss of $3.9 million. The company has significantly reduced its expenses following a transaction with Ayrmid in late 2024.